(Reuters) – Gilead Sciences Inc
Beginning March, the studies will test the drug, remdesivir, among approximately 1,000 patients at medical centers primarily across Asian countries, as well as in other countries with high numbers of diagnosed cases, the company said https://reut.rs/2wQhEjX.
(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)

